Federal Register Notice: FDA’s Oncologic Drugs Advisory Committee will meet 12/5, from 8 a.m. to 5 p.m. at the Hilton Washington DC North/Gaithersburg, The Ballrooms, 620 Perry Pkwy., Gaithersburg, MD. The committee will discuss a Genentech supplemental BLA for Avastin (bevacizumab), for the proposed indication in combination with paclitaxel, for treating patients who have not received chemotherapy for their locally recurrent or metastatic, HER2-negative breast cancer. Contact Nicole Vesely, (301) 827-6793. To view this notice, click here.